ID   MCF-7/LetR-2
AC   CVCL_5A18
SY   MCF7/LetR-2; LetR-2
DR   cancercelllines; CVCL_5A18
DR   CancerTools; 152548
DR   ECACC; 16022525
DR   Wikidata; Q54904370
DR   Ximbio; 152548
RX   PubMed=25625755;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI_6413; Letrozole.
CC   Sequence variation: Gene deletion; HGNC; HGNC:1787; CDKN2A; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line).
CC   Discontinued: ECACC; 16022525; true.
CC   Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.
ST   Source(s): ECACC=16022525
ST   Amelogenin: X
ST   CSF1PO: 10
ST   D13S317: 11
ST   D16S539: 11,12
ST   D18S51: 14
ST   D21S11: 30
ST   D3S1358: 16
ST   D5S818: 11,12
ST   D7S820: 9
ST   D8S1179: 10,14
ST   FGA: 23,25
ST   Penta D: 12
ST   Penta E: 7,12
ST   TH01: 6
ST   TPOX: 9,12
ST   vWA: 14,15
DI   NCIt; C4194; Invasive breast carcinoma of no special type
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_1D47 ! MCF-7/S0.5
SX   Female
AG   69Y
CA   Cancer cell line
DT   Created: 14-12-15; Last updated: 19-12-24; Version: 17
//
RX   PubMed=25625755; DOI=10.3892/ijo.2015.2850; PMCID=PMC4356498;
RA   Hole, Stine
RA   Pedersen, Astrid M.
RA   Hansen, Susanne K.
RA   Lundqvist, Johan
RA   Yde, Christina Westmose
RA   Lykkesfeldt, Anne E.
RT   "New cell culture model for aromatase inhibitor-resistant breast
RT   cancer shows sensitivity to fulvestrant treatment and cross-resistance
RT   between letrozole and exemestane.";
RL   Int. J. Oncol. 46:1481-1490(2015).
//